Comparison
While SS-31 improves mitochondrial bioenergetics, reduces oxidative stress, and shows protective effects in models of ischemia-reperfusion, neurodegeneration, and other mitochondrial disorders4637137, Tirzepatide is approved for type 2 diabetes and obesity, producing larger HbA1c and body-weight reductions than semaglutide in head-to-head trials24.
While SS-31 works as a mitochondria-targeted tetrapeptide, d-Arg-dimethylTyr-Lys-Phe-NH2, that selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure, improving electron transport, and reducing ROS production4637137143, Tirzepatide is a 39-amino-acid synthetic peptide primarily based on GIP sequence with C20 fatty diacid conjugation that acts as a dual agonist at GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite24.
SS-31 is 4 amino acids long, whereas Tirzepatide is longer as it has a length of 39 amino acids. SS-31 is made up of a sequence of Arginine, dimethylTyr, Lysine, Phenylalanine. Tirzepatide is made up of a sequence of sequence data not available in the current dataset.
SS-31
Not assigned in the current dataset.
Tirzepatide
Not assigned in the current dataset.